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Background. Progressive multifocal leukoencephalopathy (PML) is a fatal disease caused by reactivation of JC polyomavirus
(JCPyV) in immunosuppressed individuals and lytic infection by neurotropic JCPyV in glial cells. The exact content of neurotropic
mutations within individual JCPyV strains has not been studied to our knowledge.
Methods. We exploited the capacity of single-molecule real-time sequencing technology to determine the sequence of complete
JCPyV genomes in single reads. The method was used to precisely characterize individual neurotropic JCPyV strains of 3 patients
with PML without the bias caused by assembly of short sequence reads.
Results. In the cerebrospinal fluid sample of a 73-year-old woman with rapid PML onset, 3 distinct JCPyV populations could be
identified. All viral populations were characterized by rearrangements within the noncoding regulatory region (NCCR) and 1 point
mutation, S267L in the VP1 gene, suggestive of neurotropic strains. One patient with PML had a single neurotropic strain with re-
arranged NCCR, and 1 patient had a single strain with small NCCR alterations.
Conclusions. We report here, for the first time, full characterization of individual neurotropic JCPyV strains in the cerebrospinal
fluid of patients with PML. It remains to be established whether PML pathogenesis is driven by one or several neurotropic strains in
an individual.
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Progressive multifocal leukoencephalopathy (PML) is a neurode-
generative disorder caused by reactivation of latent JC polyoma-
virus (JCPyV) leading to lytic infection of permissive myelin-
producing oligodendrocytes and astrocytes [1, 2]. Symptoms in-
clude cognitive, motor, and visual impairment [3]. Established
risk factors for PML are underlying lymphoproliferative disor-
ders, hematopoietic stem cell or organ transplantation, or
human immunodeficiency virus infection [4]. Recently a new
PML risk group has emerged: patients with autoimmune diseas-
es, such as multiple sclerosis, Crohn’s disease, or rheumatoid dis-
eases, who are treated with biological immunomodulatory drugs,
such as natalizumab or rituximab [3]. Albeit a rare disease, PML
has a high mortality rate, influenced by the underlying immuno-
suppressive condition and its reversibility. The mortality rate in
AIDS-related PML is approximately 50% [5–7], and among na-
talizumab-treated patients with multiple sclerosis, it is about 30%
[8, 9]. The PML mortality rate among solid organ and bone mar-
row transplant recipients ranges from approximately 50% to as
high as 84% [10, 11]. Only restoration of immunocompetence
improves patient prognosis [12].
JC polyomavirus was first isolated in 1971 from brain tissue of
a patient with PML [13]. JCPyV is usually acquired in childhood
as an asymptomatic infection [14], and seroprevalence varies
from 30% up to 70% in the general population inmany countries,
including Finland [15]. Circulating archetype JC polyomaviruses
are thought to persist without causing symptoms in the host,
most probably in kidney epithelium or in bone marrow [16–
18]. PML is always associated with so called neurotropic JCPyV
strains, which emerge in the individual and do not circulate in the
population. Neurotropic strains may arise already during latency
or because of enhanced replication upon reactivation in immu-
nosuppressed individuals [19, 20]. Emergence of neurotropic
strains enhances virus spread through the blood-brain barrier,
lytic virus replication in glial cells, and ultimately PML.
Active replication may lead to accumulation of deletions and
duplications within the noncoding regulatory region (NCCR)
and point mutations in the capsid protein gene VP1 of arche-
type strains, giving rise to neurotropic strains. Neurotropic re-
arrangements are individual in each patient, but they always
occur in the NCCR and often also in VP1. The archetype
NCCR has an A-B-C-D-E block structure [21, 22]. The proto-
type neurotropic strain Mad-1 has a 98–base pair (bp) tandem
repeat of promoter/enhancer elements and deletions in B and D
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blocks compared with the archetype CY strain [20, 21]. Owing
to NCCR mutations, neurotropic strains have been shown to
replicate more efficiently than archetype strains in neuronal
cells [22, 23], and indeed all JCPyV strains found in the cerebro-
spinal fluid (CSF) of patients with PML seem to harbor muta-
tions within NCCR. VP1 mutations may be located within or
near the receptor-binding region and enhance virus tropism
and attachment to receptors on the surface of oligodendrocytes
and astrocytes in the brain [24]. In a representative study by
Reid et al [25], 100% of CSF samples from patients with PML
had NCCR rearrangements, and 81% had mutated VP1 se-
quences. The exact requirements of neurotropic rearrangements
within the NCCR and VP1 have not been established.
To precisely characterize the viral populations in PML, we ex-
ploited the capacity of single-molecule real-time (SMRT) se-
quencing technology to reveal kilobases of sequence in a
single read. No assembly of short sequence fragments was per-
formed, and thus all sequencing reads represent complete indi-
vidual viral strains. In 1 patient with PML, 3 distinct viral
populations were identified, each representing different sets of
neurotropic rearrangements within the NCCR and point muta-
tions within VP1. In 2 other patients with PML, single neuro-
tropic strains were identified. It is noteworthy that no archetype
JCPyV sequences were identified in the CSF samples. For the
first time, to the best of our knowledge, we present here the
identification of distinct viral populations in 3 patients with




Of 3 patients with PML, patient 1 was a 74-year-old woman in
whom diffuse large B-cell non-Hodgkin lymphoma had been di-
agnosed in 2009. After prednisolone and x-ray therapy, her lym-
phoma was in remission in April 2010. Relapse was established in
January 2011, followed by 6 courses of bendamustin-rituximab
treatment. Rituximab maintenance therapy was continued at 3-
month intervals. In January 2013, brain computed tomography
(CT) revealed a right-sided occipital large lesion in the white mat-
ter, and the diagnosis was PML. The patient died in March 2013.
Patient 2 was an 82-year-old man in whom follicular stage
IVA lymphoma had been diagnosed in 2002 and treated initially
with chlorambucil. After the first relapse, 6 cycles of bendamus-
tin-rituximab were administered from June to October 2004.
The second relapse was treated with 6 cycles of rituximab
from October 2007 to February 2008, followed by rituximab
maintenance treatment at 3-month intervals until March
2010. At the third relapse in September 2011 the patient pre-
sented with pain in the left leg, and MRI showed enlarged
lymph nodes in the inguinal region. He refused further exami-
nations and treatment at that time. After the fourth relapse in
March 2012, the patient received another 6 cycles of rituximab-
bendamustin. In March 2013, PML was diagnosed, and the pa-
tient died in April 2013.
Patient 3 was a 59-year-old man with no immunosuppressive
medication or condition. In August 2007, he had a partial seizure
and left-sided hemiparesis; the brain CT appearance was normal.
In September 2007, brain CT showed an infarct in the right fron-
tal lobe. In November 2007, the patient experienced epileptic sei-
zures, cognitive decline, and speech apraxia; brain CT showed
several infarcts on both sides. The symptoms progressed, and
brain magnetic resonance (MR) imaging in January 2008 showed
white matter lesions; the diagnosis was PML without severe im-
munosuppression. The patient died in February 2008.
Detailed information on the patients and their medications is
presented in Supplementary Patient Data. Ethical permission to
use patient data in the study was granted by the Coordinating Eth-
ical Committee of the Helsinki and Uusimaa Hospital District.
Quantitative TaqMan Polymerase Chain Reaction
Nucleic acids from the CSF samples (200 µL) were extracted
using an automated NucliSENS EasyMAG extraction platform
with NucliSENS Nucleic Acid Extraction reagents (bioMér-
ieux), and eluted in 25 µL of elution buffer. The polymerase
chain reaction (PCR) reaction mixture consisted of ×1 Taqman
universal PCR master mix (Applied Biosystems; Life Technolo-
gies), 900 nmol/L concentrations of each primer, 175 nmol/L
TAMRA probe (Integrated DNA Technologies), and 10 µL of
template in a 50-µL total reaction volume. The primer and
probe sequences are listed in Supplementary Table 1. Amplifi-
cation and detection were performed with an ABI PRISM 7900/
7500 cycler (Applied Biosystems) using the following cycling
conditions: 50°C for 2 minutes and 95°C for 10 minutes, fol-
lowed by 45 cycles of 95°C for 15 seconds and 60°C for 1 min-
utes. Quantification was based on an external standard curve,
using a series of plasmid dilutions.
Amplification of Full-Length JCPyV Genome
Total nucleic acids from CSF (200 µL) were extracted using an
automated Magna Pure LC 1.0 instrument and Magna Pure LC
Total Nucleic Acid Isolation kit (Roche Applied Science) and
eluted in 50 µL of elution buffer. For primer design, the
JCPyV strain Mad-1 complete genome sequence (GenBank da-
tabase, National Center of Biotechnology; accession No.
J02226.1) was used as a query to search for areas of homology
with the BLAST algorithm (http://blast.ncbi.nlm.nih.gov/Blast.
cgi). The region between nucleotides 3620 and 3663 (Mad-1)
within the large T antigen was chosen for primer targeting
(Supplementary Table 1). The 25-µL PCR reaction mixture con-
sisted of ×1 Q5 Reaction buffer (New England Biolabs), 200
µmol/L dNTP, 500 nmol/L concentrations of each primer,
0.02 U/µL Q5 Hot Start High-Fidelity DNA polymerase (New
England Biolabs), and 1 µL of template.
The PCR reactions were performed with a Tetrad 2 Peltier
Thermal cycler (Bio-Rad), as follows: 98°C for 30 seconds,
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Figure 1. Schematic representation of the principle of JC polyomavirus JCPyV sample preparation and PacBio sequencing workflow. Shown are 2 patient samples, sample 1
containing 3 and sample 2 containing 1 distinct JCPyV sequence type. A, Initial amplification of complete viral genomes using primers targeting large T antigen. B, Second
amplification with sample specific barcoded primers (see Supplementary Table 1), with barcode portions of primers marked in red. C, PacBio SMRTbell library preparation. A
hairpin adapter is attached to both ends of each amplicon molecule to enable continuous sequencing for several passes of each molecule. D, PacBio sequencing unit (single-
molecule real-time [SMRT] cell) containing 150 000-hole zero-mode waveguides. Sequencing of a single amplified viral genome molecule takes place in 1 well of the SMRT
cell, shown in the enlargement. E, Single molecule sequencing and definitions of different PacBio reads.
JC Polyomavirus Strains in PML • JID • 3
BRIEF REPORT • JID 2017:215 (15 March) • 891
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Figure 1. Schematic representation of the principle of JC polyomavirus JCPyV sample preparation and PacBio sequencing workflow. Shown are 2 patient samples, sample 1
containing 3 and sample 2 containing 1 distinct JCPyV sequence type. A, Initial amplification of complete viral genomes using primers targeting large T antigen. B, Second
amplification with sample specific barcoded primers (see Supplementary Table 1), with barcode portions of primers marked in red. C, PacBio SMRTbell library preparation. A
hairpin adapter is attached to both ends of each amplicon molecule to enable continuous sequencing for several passes of each molecule. D, PacBio sequencing unit (single-
molecule real-time [SMRT] cell) containing 150 000-hole zero-mode waveguides. Sequencing of a single amplified viral genome molecule takes place in 1 well of the SMRT
cell, shown in the enlargement. E, Single molecule sequencing and definitions of different PacBio reads.
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followed by 35 cycles of 98°C for 10 seconds, 64°C for 30 seconds,
and 72°C for 3 minutes, and the final extension of 72°C for 2
minutes. The PCR products were visualized in agarose gels. For
full-length sequencing using PacBio SMRT technology (Pacific
Biosciences), the PCR products were further amplified using the
same primers complemented with PacBio barcode sequences
(Supplementary Table 1) at their 5′ ends to add individual identi-
fiers to each sample. Robust, correct-sized (about 5.2-kb) ampli-
cons were obtained. Equal molar amounts of all full-length
barcoded PCR products were purified for sequencing.
SMRT Sequencing and Sequence Analysis
Amplicon template preparation and sequencing was done ac-
cording to the PacBio protocol. Briefly, DNA damages and
ends were first repaired, and then hairpin adapters were blunt
ligated to the purified full-length JCPyV genome amplicons to
generate the SMRTbell library. Failed ligation products were re-
moved by exonuclease treatment. The sequencing primer was
annealed to the single-stranded hairpin, and DNA polymerase
P6 was allowed to bind to the SMRTbell template. Finally, the
PacBio (Pacific Biosciences) RS II System with C4 chemistry
was used for sequencing. The Long Amplicon Analysis tool, im-
plemented in SMRT Analysis Software (version 2.3.0) with de-
fault parameters, was used to find phased circular consensus
sequence reads from barcoded amplicon pool. Obtained con-
sensus sequence reads were verified using polymerase reads rep-
resenting ≥5 full passes of the insert (individual viral genome)
with the Reads of Insert mapping tool (SMRT Analysis Soft-
ware; version 2.3.0) (minimum predicted accuracy, 80%; mini-
mum read length of insert, 4900 bp).
Sequence Alignments
For sequence comparisons, Mad-1 (J02226.1), CY (AB038249.1),
and prototype genotype 1A (AF015526.1) and 2B (AF015533.1)
sequences were retrieved from GenBank. The numbering of nu-
cleotides and amino acids presented in Results is according to
prototype strains of genotypes 1A and 2B. The numbering of nu-
cleotides within NCCR is according to the CY strain.
RESULTS
In this study, we used full-genome PCR and single-molecule se-
quencing to characterize the JCPyV populations in CSF samples
from 3 patients with PML. Full JCPyV genomes were amplified
by PCR using primers annealing to conserved regions within
the T-antigen sequence (Supplementary Table 1), and barcodes
were added for sequencing. The principle of sample preparation
and PacBio single-molecule sequencing is described in Figure 1.
The crucial difference from other novel sequencing techniques
is the capacity of PacBio to cover complete polyomavirus ge-
nomes in 1 sequencing read, which enables full characterization
of individual virus strains. All sequences are available at https://
www.ebi.ac.uk/ under Study accession number PRJEB15261.
The main characteristics and findings of the patients with
PML are shown in Table 1. All patients fulfilled the criteria for
definite PML, including clinical symptoms, typical MR findings,
and JCPyV DNA in the CSF [26]; therefore, autopsies were not
performed, and postmortem histopathological findings were not
available, nor could samples other than CSF be obtained. AnMR
image of patient 1 is shown in Supplementary Figure 1.
Patient 1 was a 74-year-old woman with rapid-onset PML.
She had been treated for diffuse large B-cell non-Hodgkin lym-
phoma with rituximab for 2 years. A total of 17 260 subreads
were obtained from Long Amplicon Analysis of a CSF sample
(Supplementary Table 2). They were coarsely clustered into 3
distinct sequence clusters 5051, 5191, and 5243 bp long
(Table 1), whereas the CY archetype sequence length is 5120
bp [14], and the Mad-1 neurotropic prototype length 5130 bp
[27]. All viral populations represented JCPyV subtype 1A.
The length differences are explained by different NCCR (blocks
A–F) lengths (185, 326, and 378 bp). The NCCR arrangements
of these strains were of types A–B–C–E–F (D deletion), A–B–
C–E–F–(C)–E–F (D deletion; E, F duplication), and A–B–C–E–
A–B–C–E–F (D deletion; large duplication including ori). An
alignment of the NCCR region is shown in Figure 2. Base cov-
erage of each sequence cluster was very high but varied from














1 9.38 × 105 5051 1 (A) A–B–C–E–F Neurotropic S267L 4732/4738
5191 1 (A) A–B–C–E–F–(C)–
E–F
Neurotropic S267L 4732/4737
5243 1 (A) A–B–C–E–A–B–C–
E–F
Neurotropic S267L 4732/4737
2 1.84 × 104 5111 1 (A) A–B–C–D–E–Fb Archetype-like G8A, L158V,
S269F, K345R
4717/4737





Abbreviations: JCPyV, JC polyomavirus; NCCR, noncoding regulatory region; PML, progressive multifocal leukoencephalopathy.
a Coding sequence identity is the proportion of identical nucleotides within protein coding genes compared with the prototype sequence for each genotype.
b A G-to-A point mutation at nucleotide 217 in the F block and a small deletion were also established.
4 • JID • Seppälä et al
713- to 1142-fold. (Supplementary Table 2). All strains also had
1 point mutation, S267L within the VP1 receptor-binding re-
gion (Table 1).
Patient 2 was an 82-year-old man with follicular stage IVA
lymphoma treated with rituximab for a total of 30 cycles. A
total of 16 200 subreads were obtained in sequencing, all repre-
senting 1 cluster of JCPyV genotype 1A (Table 1, Supplementary
Table 2). The NCCR was 246 bp long, and the arrangement was
A–B–C–D–E–F (Figure 2). A G-to-A point mutation was found
at nucleotide 217 in the F block, and a deletion of nucleotides
243–252. This strain represents an archetype-like rather than
an unequivocally neurotropic strain. Point mutations were
found within VP1, leading to amino acid changes G8A, L158V,
S269F, and K345R (Table 1). Of these, S269F is known to affect
the receptor-binding region of VP1.
Patient 3 was a 59-year-old man who developed PML with no
preceding immunosuppressive medication or condition. All
17 175 subreads clustered together and represented genotype
2B (Table 1; Supplementary Table 2). The NCCR was 269 nu-
cleotides long and diverged most from archetype NCCR se-
quences among the PML samples (Figure 2). The
arrangement was of type A–B–(C)–E–(B)–(C)–E–F (D dele-
tion; B, C, E duplication). A G-to-A point mutation was
found at nucleotide 217 in the F block, and deletion of nucleo-
tides 110–112 affecting the end of the C block. Novel VP1
amino acid changes K60N and E69Q were observed, as well
as S269F within the receptor-binding region (Table 1).
DISCUSSION
PML is a devastating disease with a high fatality rate. Its path-
ogenesis essentially involves the emergence of neurotropic
JCPyV strains having better access to glial cells and replicating
with higher efficiency than archetype circulating strains. Single-
molecule sequencing has for the first time enabled precise char-
acterization of complete neurotropic JCPyV genomes, and this
approach has been enforced in the present work. Importantly,
along with improved resolution of new sequencing techniques,
several viral strains can be differentiated in a population with
high precision. In the current study, we characterized the
JCPyV populations in CSF samples from 3 patients with
PML; in 1 patient, the presence of 3 distinct neurotropic strains
was established.
Neurotropic strains associated with PML always carry muta-
tions in the NCCR region, which may alter the composition of
transcription factor binding sites [28–30]. All 3 strains from
our patient 1 had a deletion of D block with consequent deletion
of 1 binding site for specificity protein 1 (Sp-1), deletion or ad-
dition of an SpB-binding site, and addition of an nuclear factor-1
(NF-1)–binding site. It is possible that the alterations are partially
complemented by each other. Sp-1, Spi-B, and NF-1 are known
to enhance JCPyV replication in glial cells [23, 31–35]. Our pa-
tient 2 had 1 point mutation and a 10-nucleotide deletion within
NCCR, which may be suggestive of a neurotropic strain. In pa-
tient 3, considerable rearrangements within the NCCR were ob-
served. Similar to findings in our patients 2 and 3, the G-to-A
mutation at nucleotide 217, together with other minor changes,
has been reported before in immunocompetent individuals, but
more frequently in patients with PML [21].
Many neurotropic strains also have point mutations within
the VP1 capsid protein gene, which may alter binding proper-
ties of the virus to its receptor or lead to alternative receptor
usage [24, 36]. Importantly, neurotropic mutations are always
Figure 2. Alignment of the noncoding regulatory regions (NCCR) of patient JC polyomavirus (JCPyV) strains and the CY archetype strain. NCCR sequences of mutant JCPyV
strains were compared with the archetype NCCR sequence of the CY prototype strain (in capital letters). Three NCCR sequences were found in the sample from patient 1 (5243,
5191, and 5051 base pairs) but only 1 NCCR sequence in samples from both patients 2 and 3. Sequence identities are highlighted either in dark blue (nucleotides A and G) or
light blue (nucleotides C and T).
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followed by 35 cycles of 98°C for 10 seconds, 64°C for 30 seconds,
and 72°C for 3 minutes, and the final extension of 72°C for 2
minutes. The PCR products were visualized in agarose gels. For
full-length sequencing using PacBio SMRT technology (Pacific
Biosciences), the PCR products were further amplified using the
same primers complemented with PacBio barcode sequences
(Supplementary Table 1) at their 5′ ends to add individual identi-
fiers to each sample. Robust, correct-sized (about 5.2-kb) ampli-
cons were obtained. Equal molar amounts of all full-length
barcoded PCR products were purified for sequencing.
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Amplicon template preparation and sequencing was done ac-
cording to the PacBio protocol. Briefly, DNA damages and
ends were first repaired, and then hairpin adapters were blunt
ligated to the purified full-length JCPyV genome amplicons to
generate the SMRTbell library. Failed ligation products were re-
moved by exonuclease treatment. The sequencing primer was
annealed to the single-stranded hairpin, and DNA polymerase
P6 was allowed to bind to the SMRTbell template. Finally, the
PacBio (Pacific Biosciences) RS II System with C4 chemistry
was used for sequencing. The Long Amplicon Analysis tool, im-
plemented in SMRT Analysis Software (version 2.3.0) with de-
fault parameters, was used to find phased circular consensus
sequence reads from barcoded amplicon pool. Obtained con-
sensus sequence reads were verified using polymerase reads rep-
resenting ≥5 full passes of the insert (individual viral genome)
with the Reads of Insert mapping tool (SMRT Analysis Soft-
ware; version 2.3.0) (minimum predicted accuracy, 80%; mini-
mum read length of insert, 4900 bp).
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and prototype genotype 1A (AF015526.1) and 2B (AF015533.1)
sequences were retrieved from GenBank. The numbering of nu-
cleotides and amino acids presented in Results is according to
prototype strains of genotypes 1A and 2B. The numbering of nu-
cleotides within NCCR is according to the CY strain.
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from 3 patients with PML. Full JCPyV genomes were amplified
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the T-antigen sequence (Supplementary Table 1), and barcodes
were added for sequencing. The principle of sample preparation
and PacBio single-molecule sequencing is described in Figure 1.
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is the capacity of PacBio to cover complete polyomavirus ge-
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phoma with rituximab for 2 years. A total of 17 260 subreads
were obtained from Long Amplicon Analysis of a CSF sample
(Supplementary Table 2). They were coarsely clustered into 3
distinct sequence clusters 5051, 5191, and 5243 bp long
(Table 1), whereas the CY archetype sequence length is 5120
bp [14], and the Mad-1 neurotropic prototype length 5130 bp
[27]. All viral populations represented JCPyV subtype 1A.
The length differences are explained by different NCCR (blocks
A–F) lengths (185, 326, and 378 bp). The NCCR arrangements
of these strains were of types A–B–C–E–F (D deletion), A–B–
C–E–F–(C)–E–F (D deletion; E, F duplication), and A–B–C–E–
A–B–C–E–F (D deletion; large duplication including ori). An
alignment of the NCCR region is shown in Figure 2. Base cov-
erage of each sequence cluster was very high but varied from














1 9.38 × 105 5051 1 (A) A–B–C–E–F Neurotropic S267L 4732/4738
5191 1 (A) A–B–C–E–F–(C)–
E–F
Neurotropic S267L 4732/4737
5243 1 (A) A–B–C–E–A–B–C–
E–F
Neurotropic S267L 4732/4737
2 1.84 × 104 5111 1 (A) A–B–C–D–E–Fb Archetype-like G8A, L158V,
S269F, K345R
4717/4737





Abbreviations: JCPyV, JC polyomavirus; NCCR, noncoding regulatory region; PML, progressive multifocal leukoencephalopathy.
a Coding sequence identity is the proportion of identical nucleotides within protein coding genes compared with the prototype sequence for each genotype.
b A G-to-A point mutation at nucleotide 217 in the F block and a small deletion were also established.
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713- to 1142-fold. (Supplementary Table 2). All strains also had
1 point mutation, S267L within the VP1 receptor-binding re-
gion (Table 1).
Patient 2 was an 82-year-old man with follicular stage IVA
lymphoma treated with rituximab for a total of 30 cycles. A
total of 16 200 subreads were obtained in sequencing, all repre-
senting 1 cluster of JCPyV genotype 1A (Table 1, Supplementary
Table 2). The NCCR was 246 bp long, and the arrangement was
A–B–C–D–E–F (Figure 2). A G-to-A point mutation was found
at nucleotide 217 in the F block, and a deletion of nucleotides
243–252. This strain represents an archetype-like rather than
an unequivocally neurotropic strain. Point mutations were
found within VP1, leading to amino acid changes G8A, L158V,
S269F, and K345R (Table 1). Of these, S269F is known to affect
the receptor-binding region of VP1.
Patient 3 was a 59-year-old man who developed PML with no
preceding immunosuppressive medication or condition. All
17 175 subreads clustered together and represented genotype
2B (Table 1; Supplementary Table 2). The NCCR was 269 nu-
cleotides long and diverged most from archetype NCCR se-
quences among the PML samples (Figure 2). The
arrangement was of type A–B–(C)–E–(B)–(C)–E–F (D dele-
tion; B, C, E duplication). A G-to-A point mutation was
found at nucleotide 217 in the F block, and deletion of nucleo-
tides 110–112 affecting the end of the C block. Novel VP1
amino acid changes K60N and E69Q were observed, as well
as S269F within the receptor-binding region (Table 1).
DISCUSSION
PML is a devastating disease with a high fatality rate. Its path-
ogenesis essentially involves the emergence of neurotropic
JCPyV strains having better access to glial cells and replicating
with higher efficiency than archetype circulating strains. Single-
molecule sequencing has for the first time enabled precise char-
acterization of complete neurotropic JCPyV genomes, and this
approach has been enforced in the present work. Importantly,
along with improved resolution of new sequencing techniques,
several viral strains can be differentiated in a population with
high precision. In the current study, we characterized the
JCPyV populations in CSF samples from 3 patients with
PML; in 1 patient, the presence of 3 distinct neurotropic strains
was established.
Neurotropic strains associated with PML always carry muta-
tions in the NCCR region, which may alter the composition of
transcription factor binding sites [28–30]. All 3 strains from
our patient 1 had a deletion of D block with consequent deletion
of 1 binding site for specificity protein 1 (Sp-1), deletion or ad-
dition of an SpB-binding site, and addition of an nuclear factor-1
(NF-1)–binding site. It is possible that the alterations are partially
complemented by each other. Sp-1, Spi-B, and NF-1 are known
to enhance JCPyV replication in glial cells [23, 31–35]. Our pa-
tient 2 had 1 point mutation and a 10-nucleotide deletion within
NCCR, which may be suggestive of a neurotropic strain. In pa-
tient 3, considerable rearrangements within the NCCR were ob-
served. Similar to findings in our patients 2 and 3, the G-to-A
mutation at nucleotide 217, together with other minor changes,
has been reported before in immunocompetent individuals, but
more frequently in patients with PML [21].
Many neurotropic strains also have point mutations within
the VP1 capsid protein gene, which may alter binding proper-
ties of the virus to its receptor or lead to alternative receptor
usage [24, 36]. Importantly, neurotropic mutations are always
Figure 2. Alignment of the noncoding regulatory regions (NCCR) of patient JC polyomavirus (JCPyV) strains and the CY archetype strain. NCCR sequences of mutant JCPyV
strains were compared with the archetype NCCR sequence of the CY prototype strain (in capital letters). Three NCCR sequences were found in the sample from patient 1 (5243,
5191, and 5051 base pairs) but only 1 NCCR sequence in samples from both patients 2 and 3. Sequence identities are highlighted either in dark blue (nucleotides A and G) or
light blue (nucleotides C and T).
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found in CSF and often in plasma samples, whereas archetype
sequences are mostly found in urine samples from the same pa-
tients. Rare exceptions have been reported [29]. Among our pa-
tients with PML, 2 mutations affecting the receptor-binding
region of VP1 were identified. An S267L mutation was identi-
fied in all 3 JCPyV strains from patient 1, and an S269F muta-
tion in both patients 2 and 3. Both mutations have been
reported in PML before, in both CSF and plasma samples
from patients with PML, together with another mutation,
S267Y [25, 36]. The S267L point mutation has been recognized
as a PML-associated site, although another mutation, S267F,
seems to occur more frequently, at least in serum samples
[25]. It has been speculated that mutation of this site may mod-
ify the preference of JCPyV capsids from sialylated glycans out-
side to nonsialylated glycans inside the central nervous system,
which might explain their occurrence and replication in glial
cells [24].
In the present study, it is noteworthy that the patient with ex-
ceptionally rapid onset of PML had 3 distinct JCPyV strains,
which all had different NCCR rearrangements and a mutation
putatively affecting receptor binding by VP1. The impact of this
finding on the exceptional disease pathogenesis remains to be
established. It is indeed possible that NCCR rearrangements
alone are insufficient to drive PML pathogenesis, and additional
mutations may be needed. Of note, mutations within the JCPyV
genome may also generate strains causing abortive infection,
where full replication cycle of the virus does not take place—a
phenomenon that may lead to additional disease including on-
cogenic events [37, 38].
Sequencing of complete JCPyV genomes has previously been
presented by Reid et al [25]. In that study viral sequences were
assembled from Sanger sequencing fragments, which has some
drawbacks. First, the resolution of Sanger sequencing is not op-
timal to identify distinct sequences which may be present in
smaller proportions. Second, assembly of sequence fragments
conceals their exact origin, and combinations of mutations
within a single strain may be missed. No exact information
on individual viral strains can be obtained from assembled se-
quences. However, in that work, cloning of a number of short
PCR products revealed the presence of different sequences with-
in an individual. The authors further suggested that NCCR re-
arrangements in JCPyV strains may exist with or without point
mutations within VP1, whereas VP1 mutations never exist
without NCCR rearrangements [25]. This is in agreement
with our findings, where all JCPyV strains found in CSF had
mutations both in NCCR and in the VP1 receptor-binding
region.
In our patients with PML, JCPyV genotype 1A, a common
European genotype, and an Asian genotype 2B were found
[39–42]. The patient carrying genotype 2B was indeed of East
Asian origin. Although in this particular patient PML devel-
oped without a preceding immunosuppressive condition or
medication, which might raise the question of differences be-
tween genotypes, PML risk and disease course seem indepen-
dent of genotype. The other 2 patients with PML in our study
both had genotype 1A. It has been suggested that only 1 JCPyV
genotype may be found in an individual [25], although a patient
on a natalizumab regimen for multiple sclerosis has been re-
ported to harbor 2 genotypes [30].
We found no sequences representing pure archetype JCPyV
strains in the CSF samples from patients with PML, although
the brain could be the site of selection for neurotropic strains,
which would then overgrow archetype strains due to enhanced
replication. Theoretically, both archetype and neurotropic
strains should be present at some stage of PML pathogenesis
in the site of virus strain selection. The possibility cannot be
excluded that tiny amounts of archetype strains may have re-
mained undetected despite the great depth of PacBio sequenc-
ing. Although neurotropic or altered strains are always found in
the brain with PML and their enhanced replication relative to
archetype strains has been established, archetype strains have
occasionally been detected in the brain as well [20, 43].
To our knowledge this is the first report to characterize indi-
vidual full-length neurotropic JCPyV strains as well as whole
viral populations of patients with PML. Understanding of the
biological behavior of different neurotropic JCPyV strains
with different combinations of rearrangements is important, be-
cause viral load in CSF does not correlate with disease course or
survival. The presence of several neurotropic strains within an
individual is an intriguing finding. Whether all strains or only
one drive PML pathogenesis and whether additive effects take
place need further exploration. Information on all neurotropic
rearrangements within individual viral strains will contribute to
our understanding of JCPyV neurotropism and the pathogene-
sis of PML.
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found in CSF and often in plasma samples, whereas archetype
sequences are mostly found in urine samples from the same pa-
tients. Rare exceptions have been reported [29]. Among our pa-
tients with PML, 2 mutations affecting the receptor-binding
region of VP1 were identified. An S267L mutation was identi-
fied in all 3 JCPyV strains from patient 1, and an S269F muta-
tion in both patients 2 and 3. Both mutations have been
reported in PML before, in both CSF and plasma samples
from patients with PML, together with another mutation,
S267Y [25, 36]. The S267L point mutation has been recognized
as a PML-associated site, although another mutation, S267F,
seems to occur more frequently, at least in serum samples
[25]. It has been speculated that mutation of this site may mod-
ify the preference of JCPyV capsids from sialylated glycans out-
side to nonsialylated glycans inside the central nervous system,
which might explain their occurrence and replication in glial
cells [24].
In the present study, it is noteworthy that the patient with ex-
ceptionally rapid onset of PML had 3 distinct JCPyV strains,
which all had different NCCR rearrangements and a mutation
putatively affecting receptor binding by VP1. The impact of this
finding on the exceptional disease pathogenesis remains to be
established. It is indeed possible that NCCR rearrangements
alone are insufficient to drive PML pathogenesis, and additional
mutations may be needed. Of note, mutations within the JCPyV
genome may also generate strains causing abortive infection,
where full replication cycle of the virus does not take place—a
phenomenon that may lead to additional disease including on-
cogenic events [37, 38].
Sequencing of complete JCPyV genomes has previously been
presented by Reid et al [25]. In that study viral sequences were
assembled from Sanger sequencing fragments, which has some
drawbacks. First, the resolution of Sanger sequencing is not op-
timal to identify distinct sequences which may be present in
smaller proportions. Second, assembly of sequence fragments
conceals their exact origin, and combinations of mutations
within a single strain may be missed. No exact information
on individual viral strains can be obtained from assembled se-
quences. However, in that work, cloning of a number of short
PCR products revealed the presence of different sequences with-
in an individual. The authors further suggested that NCCR re-
arrangements in JCPyV strains may exist with or without point
mutations within VP1, whereas VP1 mutations never exist
without NCCR rearrangements [25]. This is in agreement
with our findings, where all JCPyV strains found in CSF had
mutations both in NCCR and in the VP1 receptor-binding
region.
In our patients with PML, JCPyV genotype 1A, a common
European genotype, and an Asian genotype 2B were found
[39–42]. The patient carrying genotype 2B was indeed of East
Asian origin. Although in this particular patient PML devel-
oped without a preceding immunosuppressive condition or
medication, which might raise the question of differences be-
tween genotypes, PML risk and disease course seem indepen-
dent of genotype. The other 2 patients with PML in our study
both had genotype 1A. It has been suggested that only 1 JCPyV
genotype may be found in an individual [25], although a patient
on a natalizumab regimen for multiple sclerosis has been re-
ported to harbor 2 genotypes [30].
We found no sequences representing pure archetype JCPyV
strains in the CSF samples from patients with PML, although
the brain could be the site of selection for neurotropic strains,
which would then overgrow archetype strains due to enhanced
replication. Theoretically, both archetype and neurotropic
strains should be present at some stage of PML pathogenesis
in the site of virus strain selection. The possibility cannot be
excluded that tiny amounts of archetype strains may have re-
mained undetected despite the great depth of PacBio sequenc-
ing. Although neurotropic or altered strains are always found in
the brain with PML and their enhanced replication relative to
archetype strains has been established, archetype strains have
occasionally been detected in the brain as well [20, 43].
To our knowledge this is the first report to characterize indi-
vidual full-length neurotropic JCPyV strains as well as whole
viral populations of patients with PML. Understanding of the
biological behavior of different neurotropic JCPyV strains
with different combinations of rearrangements is important, be-
cause viral load in CSF does not correlate with disease course or
survival. The presence of several neurotropic strains within an
individual is an intriguing finding. Whether all strains or only
one drive PML pathogenesis and whether additive effects take
place need further exploration. Information on all neurotropic
rearrangements within individual viral strains will contribute to
our understanding of JCPyV neurotropism and the pathogene-
sis of PML.
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